Abstract
Polo-like kinase 1 (Plk1) is a decisive enzyme with its multifunctional activity in cell cycle progression especially mitosis. The over expression of Plk1 in broad spectrum of cancer types turns into a promising therapeutic target against cancer. In the present study, several ligand based pharmacophore models and atom based 3D-QSAR models have been generated using a series of 49 thiazole and thiophene derivatives with well prescribed Plk1 inhibitory activity. From the generated models, the AADRR hypothesis associated with an atom based 3D-QSAR model provided a satisfactory statistical significance containing predictive ability of 40 training set (R2 = 0.9539, SD = 0.1789, F = 113.8) and nine test set (Q2 = 0.4868, RMSE = 0.5333, Pearson R = 0.7114) molecules. The Hypothesis, AADRR explains the salient structural features of the molecules and the developed 3D-QSAR model points out the effect of hydrophobic groups, electron withdrawing groups and H-bond donor groups on Plk1 inhibition for the most active compound 47. The results were further supported by molecular docking studies, which explain the hydrogen bond interactions and binding mode of the ligands with Plk1. These molecular modelling results are expected to be useful for further design of active Plk1 inhibitors.
Keywords: 3D-QSAR, docking, pharmacophore modeling, Polo-like kinase 1 (Plk1), thiazole, thiophene.
Combinatorial Chemistry & High Throughput Screening
Title:Ligand-Based Pharmacophore Modeling, Atom-Based 3D-QSAR and Molecular Docking Studies on Substituted Thiazoles and Thiophenes as Polo-Like Kinase 1 (Plk1) Inhibitors
Volume: 17 Issue: 10
Author(s): Rajasekhar Chekkara, Venkata Reddy Gorla, Ethiraj Susithra and Sobha Rani Tenkayala
Affiliation:
Keywords: 3D-QSAR, docking, pharmacophore modeling, Polo-like kinase 1 (Plk1), thiazole, thiophene.
Abstract: Polo-like kinase 1 (Plk1) is a decisive enzyme with its multifunctional activity in cell cycle progression especially mitosis. The over expression of Plk1 in broad spectrum of cancer types turns into a promising therapeutic target against cancer. In the present study, several ligand based pharmacophore models and atom based 3D-QSAR models have been generated using a series of 49 thiazole and thiophene derivatives with well prescribed Plk1 inhibitory activity. From the generated models, the AADRR hypothesis associated with an atom based 3D-QSAR model provided a satisfactory statistical significance containing predictive ability of 40 training set (R2 = 0.9539, SD = 0.1789, F = 113.8) and nine test set (Q2 = 0.4868, RMSE = 0.5333, Pearson R = 0.7114) molecules. The Hypothesis, AADRR explains the salient structural features of the molecules and the developed 3D-QSAR model points out the effect of hydrophobic groups, electron withdrawing groups and H-bond donor groups on Plk1 inhibition for the most active compound 47. The results were further supported by molecular docking studies, which explain the hydrogen bond interactions and binding mode of the ligands with Plk1. These molecular modelling results are expected to be useful for further design of active Plk1 inhibitors.
Export Options
About this article
Cite this article as:
Chekkara Rajasekhar, Gorla Reddy Venkata, Susithra Ethiraj and Tenkayala Rani Sobha, Ligand-Based Pharmacophore Modeling, Atom-Based 3D-QSAR and Molecular Docking Studies on Substituted Thiazoles and Thiophenes as Polo-Like Kinase 1 (Plk1) Inhibitors, Combinatorial Chemistry & High Throughput Screening 2014; 17 (10) . https://dx.doi.org/10.2174/1386207317666141024152910
DOI https://dx.doi.org/10.2174/1386207317666141024152910 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Understanding the Interaction Between Human Serum Albumin and Anti-Bacterial/ Anti-Cancer Compounds
Current Pharmaceutical Design Strategies for Development of Antimalarials Based on Encapsulated Porphyrin Derivatives
Mini-Reviews in Medicinal Chemistry Ovarian Cancer Biomarkers: Headway Towards Early Diagnosis
Current Chemical Biology Past, Present and Future of Nutrigenomics and its Influence on Drug Development
Current Drug Discovery Technologies Graphical Abstracts:
Current Radiopharmaceuticals Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Identification of a RhoA- and SRF-Dependent Mechanism of Androgen Action that is Associated with Prostate Cancer Progression
Current Drug Targets Treatment for Cancer Patients with Oral Mucositis: Assessment Based on the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer in International Society of Oral Oncology (MASCC/ISOO) in 2013 and Proposal of Possible Novel Treatment with a Japanese Herbal Medicine
Current Pharmaceutical Design Research Progress of Axl Inhibitors
Current Topics in Medicinal Chemistry Focal Adhesion Kinase as a Cancer Therapy Target
Anti-Cancer Agents in Medicinal Chemistry MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Cisplatin Is a DNA-Damaging Antitumour Compound Triggering Multifactorial Biochemical Responses in Cancer Cells: Importance of Apoptotic Pathways
Current Medicinal Chemistry - Anti-Cancer Agents Regeneration of the Gastric Mucosa and its Glands from Stem Cells
Current Medicinal Chemistry Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor
Combinatorial Chemistry & High Throughput Screening “Metabolic Reprogramming” in Ovarian Cancer Cells Resistant to Cisplatin
Current Cancer Drug Targets Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal Functions of Polo-Like Kinases: A Journey From Yeast To Humans
Protein & Peptide Letters Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Current Medicinal Chemistry Novel VEGF-independent Strategies Targeting Tumor Vasculature: Clinical Aspects
Current Pharmaceutical Design The Role of Hesperidin in Cell Signal Transduction Pathway for the Prevention or Treatment of Cancer
Current Medicinal Chemistry